USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown Sells 5,000 Shares

USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares in the company, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

USANA Health Sciences Stock Up 1.3 %

USNA traded up $0.38 during trading on Monday, hitting $29.97. 287,508 shares of the stock were exchanged, compared to its average volume of 169,645. USANA Health Sciences, Inc. has a 1-year low of $27.71 and a 1-year high of $50.32. The stock has a fifty day moving average price of $33.42 and a two-hundred day moving average price of $36.47. The firm has a market capitalization of $571.21 million, a P/E ratio of 10.59, a PEG ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. Analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. DA Davidson lowered their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday. Finally, StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

Institutional Investors Weigh In On USANA Health Sciences

Large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio grew its position in USANA Health Sciences by 635.5% in the 4th quarter. Public Employees Retirement System of Ohio now owns 5,075 shares of the company’s stock valued at $182,000 after buying an additional 4,385 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of USANA Health Sciences by 83.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,300 shares of the company’s stock worth $621,000 after acquiring an additional 7,877 shares during the period. Millennium Management LLC purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $633,000. Lazard Asset Management LLC boosted its holdings in shares of USANA Health Sciences by 24,765.5% in the fourth quarter. Lazard Asset Management LLC now owns 7,211 shares of the company’s stock valued at $258,000 after acquiring an additional 7,182 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of USANA Health Sciences by 16.7% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 128,976 shares of the company’s stock worth $4,629,000 after acquiring an additional 18,490 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.